Lupin receives US-FDA approval to market generic hypertension drug

Lupin receives US-FDA approval to market generic hypertension drug

By, Admin 15 January 2024

Drug maker Lupin on Sunday said it has received approval from the US health regulator to market a generic hypertension drug in America.

The company has received approval from the US Food and Drug Administration (USFDA) for Propranolol Hydrochloride extended-release capsules in multiple strengths, Lupin Ltd said in a regulatory filing.

The company's product is the generic version of ANI Pharmaceuticals' Inderal LA extended-release capsules, it added.

The product will be manufactured at the company's Pithampur-based manufacturing plant, the drug firm stated.

Propranolol Hydrochloride extended-release capsules USP are indicated in the management of hypertension.They may be used alone or in combination with other antihypertensive agents, particularly a thiazide diuretic.

As per IQVIA MAT November 2023 data, Propranolol Hydrochloride extended-release capsules had estimated annual sales of USD 71 million in the US.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!